

Title: Cancer Treatments

Reference Number: RDF1409-23

Date of Response: 21/04/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1<sup>st</sup> April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

*Dear Royal Devon University Healthcare NHS Foundation Trust,*

*I would be grateful if you could please answer these questions relating to the usage of Dabrafenib + Trametinib in cancer treatment.*

*A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:*

- i. Metastatic Melanoma*
- ii. Adjuvant Melanoma*
- iii. BRAF mutated Lung Cancer*

Answer: Please see table below. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

	<i>Royal Devon Total No. patients*</i>
<i>Metastatic Melanoma</i>	13
<i>Adjuvant Melanoma</i>	≤5
<i>BRAF mutated Lung Cancer</i>	≤5

\* Previous 6 months date range: 01/10/2022 – 19/04/2023